BNP Paribas Exane raises Oracle stock price target to $377 on OCI growth

Published 10/09/2025, 18:20
BNP Paribas Exane raises Oracle stock price target to $377 on OCI growth

Investing.com - BNP Paribas Exane raised its price target on Oracle (NYSE:ORCL) to $377.00 from $272.00 on Wednesday, while maintaining an Outperform rating on the stock. The new target sits well above the current stock price of $335.28, with Oracle trading near its 52-week high after delivering a remarkable 63% return over the past six months. According to InvestingPro analysis, the stock appears overvalued at current levels.

The significant price target increase reflects BNP Paribas Exane’s higher outer-year non-GAAP EPS forecasts after incorporating management’s new Oracle Cloud Infrastructure (OCI) revenue targets.

The research firm expects Oracle to achieve substantial fixed cost and operating expense leverage over the coming years, despite rising depreciation costs.

BNP Paribas Exane projects Oracle will deliver more than 20% EPS growth through fiscal year 2030, supporting the higher valuation target.

The firm continues to value Oracle based on a 32.5x FY29 non-GAAP P/E ratio, discounted back to present value.

In other recent news, Oracle has seen significant developments in its financial outlook and strategic initiatives. The company reported a remarkable $317 billion quarter-over-quarter increase in remaining performance obligations, driven by several large AI contracts. This unprecedented growth led TD Cowen to raise its price target for Oracle to $375 while maintaining a Buy rating. Similarly, BMO Capital increased its price target to $345, citing Oracle’s strong bookings and a 359% year-over-year growth in remaining performance obligations. Piper Sandler also raised its price target to $330, emphasizing Oracle’s transformation into a leader in AI infrastructure.

In addition to financial updates, Oracle launched an AI Center of Excellence for Healthcare to assist organizations in implementing AI solutions. This initiative aims to provide healthcare systems with resources and expertise for AI experimentation and implementation. Furthermore, Oracle plans to integrate AI capabilities into its Health Patient Portal by 2026. This integration will allow patients to interact with their medical records using conversational AI, offering explanations and insights into complex medical information. These recent developments highlight Oracle’s strategic focus on AI and healthcare innovation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.